IL290892A - Methods of treating vascular diseases - Google Patents

Methods of treating vascular diseases

Info

Publication number
IL290892A
IL290892A IL290892A IL29089222A IL290892A IL 290892 A IL290892 A IL 290892A IL 290892 A IL290892 A IL 290892A IL 29089222 A IL29089222 A IL 29089222A IL 290892 A IL290892 A IL 290892A
Authority
IL
Israel
Prior art keywords
methods
vascular diseases
treating vascular
treating
diseases
Prior art date
Application number
IL290892A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astellas Inst For Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Inst For Regenerative Medicine filed Critical Astellas Inst For Regenerative Medicine
Publication of IL290892A publication Critical patent/IL290892A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Reproductive Health (AREA)
  • Materials For Medical Uses (AREA)
  • Gynecology & Obstetrics (AREA)
IL290892A 2019-08-28 2022-02-24 Methods of treating vascular diseases IL290892A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962892712P 2019-08-28 2019-08-28
PCT/US2020/048080 WO2021041592A1 (en) 2019-08-28 2020-08-27 Methods of treating vascular diseases

Publications (1)

Publication Number Publication Date
IL290892A true IL290892A (en) 2022-04-01

Family

ID=72422305

Family Applications (1)

Application Number Title Priority Date Filing Date
IL290892A IL290892A (en) 2019-08-28 2022-02-24 Methods of treating vascular diseases

Country Status (10)

Country Link
US (1) US20220280572A1 (cg-RX-API-DMAC7.html)
EP (1) EP4022042A1 (cg-RX-API-DMAC7.html)
JP (1) JP7876440B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220054359A (cg-RX-API-DMAC7.html)
CN (1) CN115003800A (cg-RX-API-DMAC7.html)
AU (1) AU2020337929B2 (cg-RX-API-DMAC7.html)
CA (1) CA3151637A1 (cg-RX-API-DMAC7.html)
IL (1) IL290892A (cg-RX-API-DMAC7.html)
TW (1) TW202122577A (cg-RX-API-DMAC7.html)
WO (1) WO2021041592A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
US20230027007A1 (en) * 2021-07-02 2023-01-26 Regeneron Pharmaceuticals, Inc. Treatment of Hypertension With Solute Carrier Family 9 Isoform A3 Regulatory Factor 2 (SLC9A3R2) Inhibitors
CN116832051B (zh) * 2023-07-08 2024-02-09 首都医科大学 抗氧化抗炎和促脂质代谢协同纳米给药系统

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070083A2 (en) * 2002-02-15 2003-08-28 Cornell Research Foundation, Inc. Endothelial precursor cells for enhancing and restoring vascular function
AU2007238660C1 (en) 2006-04-14 2013-11-07 Astellas Institute For Regenerative Medicine Hemangio-colony forming cells
CN101534747A (zh) * 2006-07-10 2009-09-16 哥伦比亚大学 从组织祖细胞和血管祖细胞从头形成和再生血管化组织
BRPI0912201A2 (pt) 2008-05-06 2019-09-24 Advanced Cell Tech Inc células formadoras de colônias de hemangios e células de hemangio não enxertantes
KR101920891B1 (ko) * 2010-08-27 2018-11-21 조슈아 엠 헤어 심장 치료를 위한 골수 유래 ｃｄ271 전구 세포
PL2785359T3 (pl) 2011-11-30 2018-12-31 Astellas Institute For Regenerative Medicine Mezenchymalne komórki zrębowe i związane z nimi zastosowania
US9428732B2 (en) * 2011-12-05 2016-08-30 Primorigen Biosciences, Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
JP6746313B2 (ja) * 2012-08-01 2020-08-26 ユナイテッド セラピューティクス コーポレイション プロスタサイクリン処理された内皮前駆細胞による肺動脈性高血圧症の処置
CA2896053A1 (en) * 2012-12-21 2014-06-26 Ocata Therapeutics, Inc. Methods for production of platelets from pluripotent stem cells and compositions thereof
EP2970912B1 (en) * 2013-03-13 2019-03-06 Wisconsin Alumni Research Foundation Methods and materials for hematoendothelial differentiation of human pluripotent stem cells under defined conditions
CA2930304A1 (en) * 2013-11-13 2015-05-21 Cornell University Post-natal hematopoeitic endothelial cells and their isolation and use
US10626372B1 (en) * 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
KR102411018B1 (ko) 2015-08-18 2022-06-20 아스텔라스 인스티튜트 포 리제너러티브 메디슨 임상 제제
EP3383182B1 (en) * 2015-12-03 2023-06-07 The Brigham and Women's Hospital, Inc. Methods for generating functional hematopoietic stem cells
US11345895B2 (en) * 2016-11-18 2022-05-31 Wisconsin Alumni Research Foundation Induction of arterial-type of hemogenic endothelium (AHE) and enhancement of T cell production from PSCs through overexpression of ETS factors or modulating MAPK/ERK signalling pathways

Also Published As

Publication number Publication date
TW202122577A (zh) 2021-06-16
WO2021041592A9 (en) 2021-06-24
AU2020337929B2 (en) 2026-07-16
US20220280572A1 (en) 2022-09-08
JP2022547832A (ja) 2022-11-16
WO2021041592A1 (en) 2021-03-04
AU2020337929A1 (en) 2022-03-24
JP7876440B2 (ja) 2026-06-19
CA3151637A1 (en) 2021-03-04
KR20220054359A (ko) 2022-05-02
EP4022042A1 (en) 2022-07-06
CN115003800A (zh) 2022-09-02
WO2021041592A8 (en) 2021-04-01

Similar Documents

Publication Publication Date Title
IL276383A (en) Treatment of ophthalmological diseases
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
PT4076461T (pt) Lumateperona para utilização no tratamento da esquizofrenia
SG11202006374VA (en) Treatment of demyelinating diseases
ZA202006234B (en) Compositions and methods for the treatment of neurological diseases
IL282643A (en) Soft combinations for the treatment of hematological diseases
IL282360A (en) Treatment for neurological diseases
IL287802A (en) Preparations and methods for the treatment of eye diseases
IL290983A (en) Treatment methods
GB201805100D0 (en) Treatment of sarcopenic diseases
IL269698B (en) Methods for preventing or treating eye diseases
SG11202107017TA (en) Methods of treating cancer
IL287250A (en) treatment method
PT3761982T (pt) Utilização da nalfurafina no tratamento de doenças desmielinizantes
GB202005231D0 (en) Method of mimimising patient risk
GB202015959D0 (en) Treatment of diseases involving NAD
IL290770A (en) Compounds and methods for treating oxalate-related diseases
GB201820098D0 (en) Methods of cancer treatment
GB201918853D0 (en) Methods of treatment
IL286099A (en) Methods of treating disease with levoketoconazole
IL268111A (en) Methods of treating pain
HK40074334A (en) Methods of treating vascular diseases
GB201820975D0 (en) Methods of cancer treatment
GB201909438D0 (en) Treatment of diseases
GB201900942D0 (en) Methods of treatment